Latest research on Oxycodone

Semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. [PubChem]

Latest findings

According to the principles of the three-step Analgesic ladder, Oxycodone is a first-line choice for treating moderate-to-severe cancer pain, and its controlled-release formulation, OxyContin, is a key drug for treating moderate-to-severe pain. [source, 2016]
Oxycodone has no capping dose due to the absence of a “ceiling” effect. [source, 2016]
However, the Oxycodone dosage is restricted for various reasons in clinical practice. [source, 2016]
This article reports the use of high-dose OxyContin to treat a patient who was admitted to our hospital, with the aim of providing a reference for the clinical application of Oxycodone. [source, 2016]
The time of the first Oxycontin dose was used as the baseline in this report. [source, 2016]
The patient was first administered Oxycontin on November 20, 2013, with titration starting AT 10 mg Q12h. [source, 2016]
During the period when Oxycontin was used, Ibuprofen controlled-release capsules, carbamazepine, Gabapentin, and Alprazolam were utilized as adjuvant medications based on symptoms and clinical reactions (Table 1). [source, 2016]
OxyContin is a controlled-release Oxycodone hydrochloride tablet for oral administration. [source, 2016]
Oxycontin is currently the first-choice drug for treating moderate-to-severe pain.2 [source, 2016]
At the end stage of the disease, the Analgesic effect of Oxycontin at 600 mg Q12h did not last for 12 hours, and the patient refused to take additional dose increments at each drug administration. [source, 2016]